The combination of VISTA and PD-1/CTLA-4 blockade was also shown to exert complementary effects on T cells, leading to an increased population of mature cells required for tumor cell killing and supporting the hypothesis that anti-VISTA treatment may ameliorate the adaptive resistance that can develop with contemporary ICI therapies (42). The gene discussed is VSIR; the disease is neoplasm.